KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Total Debt (2020 - 2025)

Fulgent Genetics (FLGT) has disclosed Total Debt for 6 consecutive years, with $30.1 million as the latest value for Q4 2025.

  • Quarterly Total Debt changed 0.0% to $30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.1 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $30.1 million for FY2025, 0.0% changed from the prior year.
  • Total Debt hit $30.1 million in Q4 2025 for Fulgent Genetics, down from $30.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $30.5 million in Q3 2025 to a low of $6.5 million in Q2 2021.
  • Historically, Total Debt has averaged $22.0 million across 5 years, with a median of $21.1 million in 2021.
  • Biggest five-year swings in Total Debt: surged 8082.16% in 2021 and later decreased 28.76% in 2022.
  • Year by year, Total Debt stood at $15.1 million in 2021, then increased by 21.36% to $18.4 million in 2022, then surged by 39.7% to $25.7 million in 2023, then rose by 17.3% to $30.1 million in 2024, then changed by 0.0% to $30.1 million in 2025.
  • Business Quant data shows Total Debt for FLGT at $30.1 million in Q4 2025, $30.5 million in Q3 2025, and $29.6 million in Q2 2025.